$85.45
1.26%
Downside
Day's Volatility :1.95%
Upside
0.7%
32.5%
Downside
52 Weeks Volatility :38.28%
Upside
8.56%
Period | Intra-cellular Therapies, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 13.15% | -7.6% | 0.0% |
6 Months | 27.82% | -2.3% | 0.0% |
1 Year | 46.32% | 10.1% | 0.0% |
3 Years | 107.61% | 7.5% | -24.5% |
Market Capitalization | 8.8B |
Book Value | $10.80 |
Earnings Per Share (EPS) | -0.87 |
PEG Ratio | 0.0 |
Wall Street Target Price | 101.867 |
Profit Margin | -14.07% |
Operating Margin TTM | -22.15% |
Return On Assets TTM | -7.45% |
Return On Equity TTM | -9.9% |
Revenue TTM | 613.7M |
Revenue Per Share TTM | 6.1 |
Quarterly Revenue Growth YOY | 39.0% |
Gross Profit TTM | 95.2M |
EBITDA | -121.1M |
Diluted Eps TTM | -0.87 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.7 |
EPS Estimate Next Year | 0.21 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.16 |
What analysts predicted
Upside of 18.59%
Sell
Neutral
Buy
Intra-cellular Therapies, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Intra-cellular Therapies, Inc. | 11.35% | 27.82% | 46.32% | 107.61% | 803.38% |
Neurocrine Biosciences Inc. | 5.76% | -12.28% | 12.48% | 43.36% | 8.39% |
Haleon Plc Spon Ads | -5.01% | 11.27% | 13.94% | 27.94% | 27.94% |
Zoetis Inc. | -7.27% | 1.67% | -1.71% | -21.69% | 46.12% |
Viatris Inc. | 13.48% | 19.8% | 39.98% | 0.08% | -19.65% |
Catalent, Inc. | -1.96% | 7.35% | 48.09% | -54.14% | 14.45% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Intra-cellular Therapies, Inc. | NA | NA | 0.0 | -0.7 | -0.1 | -0.07 | NA | 10.8 |
Neurocrine Biosciences Inc. | 31.77 | 32.88 | 0.28 | 6.54 | 0.16 | 0.12 | NA | 26.87 |
Haleon Plc Spon Ads | 28.58 | 28.73 | 1.69 | 0.34 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 33.0 | 33.0 | 2.46 | 5.87 | 0.47 | 0.15 | 0.01 | 11.59 |
Viatris Inc. | 224.4 | NA | 0.08 | 2.67 | -0.04 | 0.02 | 0.04 | 16.58 |
Catalent, Inc. | 211.02 | NA | 2.95 | 0.2 | -0.11 | 0.0 | NA | 19.52 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Intra-cellular Therapies, Inc. | Buy | $8.8B | 803.38% | NA | -14.07% |
Neurocrine Biosciences Inc. | Buy | $12.1B | 8.39% | 31.77 | 17.21% |
Haleon Plc Spon Ads | Buy | $42.6B | 27.94% | 28.58 | 10.75% |
Zoetis Inc. | Buy | $79.2B | 46.12% | 33.0 | 26.55% |
Viatris Inc. | Hold | $15.1B | -19.65% | 224.4 | -5.87% |
Catalent, Inc. | Hold | $10.7B | 14.45% | 211.02 | -9.34% |
Insights on Intra-cellular Therapies, Inc.
Revenue is up for the last 19 quarters, 882.51K → 175.15M (in $), with an average increase of 22.5% per quarter
Netprofit is down for the last 3 quarters, -15.24M → -26.32M (in $), with an average decrease of 34.3% per quarter
In the last 1 year, Catalent, Inc. has given 48.1% return, outperforming this stock by 1.8%
FMR Inc
Vanguard Group Inc
BlackRock Inc
Wasatch Advisors LP
JPMorgan Chase & Co
venBio Select Advisor LLC
Intra-cellular Therapies, Inc.’s price-to-earnings ratio stands at None
Read Moreintra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
Organization | Intra-cellular Therapies, Inc. |
Employees | 610 |
CEO | Dr. Sharon Mates Ph.D. |
Industry | Health Technology |
Xp Inc.
$85.45
-0.22%
Evolent Health, Inc. - Class A Shares
$85.45
-0.22%
Cullen/frost Bankers, Inc.
$85.45
-0.22%
Dimensional Us Core Equity M
$85.45
-0.22%
Silicon Laboratories Inc
$85.45
-0.22%
Sensient Technologies Corp
$85.45
-0.22%
Option Care Health Inc
$85.45
-0.22%
Summit Materials, Inc.
$85.45
-0.22%
American States Water Co
$85.45
-0.22%